Skip to main content
Premium Trial:

Request an Annual Quote

Panagene Licenses PNA Tech From Copenhagen Inventor Group

NEW YORK (GenomeWeb News) — Panagene has licensed PNA monomers from the Copenhagen Inventor Group that allows Panagene to synthesize, make, and sell peptide nucleic acids, the company said Tuesday.
 
The South Korean company adds this license agreement to a previous one with CIG for patents for PNA custom synthesis.
 
Panagene estimated that it is currently around 5 percent of the DNA/RNA synthesis market and said the new license will enable it to increase this share “significantly.”

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.